UNCOVERED: 2 - Caught on Camera

Do Wall Street Analysts Like Boston Scientific Stock?

As Boston Scientific has outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart · Oct 31, 2025

Targa Resources, Take-Two Interactive, Boston Scientific: Why Experts Rate These Stocks at Strong Buy

Wall Street is highly bullish on these three high-quality stocks.

Kiplinger · Oct 28, 2025

Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion.

Benzinga · Oct 23, 2025

Boston Scientific To Acquire Nalu Medical In $600 Million Pain Relief Deal

Boston Scientific Corp (NYSE:BSX) announced on Friday that it has agreed to acquire Nalu Medical Inc., a privately held maker of minimally invasive devices for chronic pain treatment.

Benzinga · Oct 17, 2025

What You Need To Know Ahead of Boston Scientific's Earnings Release

Boston Scientific is poised to release its third-quarter results later this month, and analysts project a double-digit earnings growth.

Barchart · Oct 6, 2025

Boston Scientific To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga · Oct 1, 2025

Top 3 Health Care Stocks That May Explode In September

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga · Sep 19, 2025

Is Boston Scientific Stock Outperforming the S&P 500?

As Boston Scientific has outpaced the S&P 500 Index over the past year, analysts are strongly optimistic about the stock’s prospects.

Barchart · Sep 3, 2025

3 Biotech Catalysts Present Major Opportunity

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

MarketBeat · Aug 25, 2025

Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy.

Benzinga · Aug 8, 2025